(Q28444937)

English

BRCA1 Loss-of-function

genetic variant

LOSS-OF-FUNCTION

In more languages

Statements

loss of heterozygosity

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

Loss Of Function Variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

human chromosome 17

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

41197646

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

41277500

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

positive therapeutic predictor for

medical condition treated

Her2-receptor negative breast cancer

determination method

CIViC evidence level B

CIViC 5-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5815

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

medical condition treated

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4876

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

medical condition treated

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4838

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

medical condition treated

prostate cancer

determination method

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/845

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

medical condition treated

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/211

Advanced ovarian cancer: what should be the standard of care?

negative prognostic predictor for

prostate cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1523

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/131

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444937&oldid=2014800997"